Josh Sommer Named To Forbes' "30 Under 30" List

Congratulations to our good friend, Josh Sommer, Executive Director of the Chordoma Foundation, for making Forbes magazine's "30 Under 30" list!  The annual list is a who's who of the nation's top young disruptors, innovators and entrepreneurs. 

Josh was diagnosed with clival chordoma in 2006 while attending Duke University.  Chordoma is a rare type of cancer that occurs in the bones of the skull and spine.  Determined to find his own cure, Josh volunteered for two years in an oncology lab at Duke. In 2008, he received a two-year Echoing Green Fellowship for Social Entrepreneurs for his pioneering work in bridging patient advocacy and research. 

Josh founded his organization to unite patients, doctors and scientists to accelerate treatments for chordoma. He strongly believes that patients can and should play an active role in bringing about treatments for their own conditions.

When Max Wallace, CEO of Accelerate Brain Cancer Cure, first met Josh in 2008 he was impressed with Josh's entrepreneurial drive and singular focus.  They immediately bonded and considered themselves to be fellow soldiers in the fight against rare diseases.  As a result, the two organizations have built strategic alliances and worked together on a variety of rare disease initiatives. In 2010, Josh participated in our Annual Scientific Gathering.  In 2011, ABC2 and the Chordoma Foundation co-hosted a National Cancer Institute meeting of the Director's Consumer Liaison Group in Research Triangle Park, NC.

 

Newsletter Issue: 
Share |
February 27, 2014 04:35 PM
ABC2's Max Wallace leads the NCI's Director's Consumer Liaison Group that addresses research issues critical to improving outcomes for patients with all types of cancers.
February 26, 2014 12:00 AM
The coalition includes Accelerate Brain Cancer Cure, the Musella Foundation for Brain Tumor Research and Information, the National Brain Tumor Society and the Society for Neuro-Oncology.
February 20, 2014 03:29 PM
An in-depth update from Medscape on the debate surrounding the use of Avastin in treating GBM.  ABC2's petitioning of the FDA is noted.

Join us in our fight for a cure!

Twitter